Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00698815 · View on ClinicalTrials.gov ↗
Study Summary
This randomized phase II trial studies pemetrexed disodium and sunitinib malate to compare how well they work when given alone or together as second-line therapy in treating patients with stage IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether pemetrexed disodium and sunitinib malate are more effective when given alone or together in treating non-small cell lung cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Pemetrexed Disodium
- DRUG Sunitinib Malate
Study Locations (20)
California
- Kaiser Permanente-Anaheim — Anaheim
- Arroyo Grande Community — Arroyo Grande
- Kaiser Permanente-Baldwin Park — Baldwin Park
- Kaiser Permanente-Bellflower — Bellflower
- East Bay Radiation Oncology Center — Castro Valley
- Eden Hospital Medical Center — Castro Valley
- Valley Medical Oncology Consultants-Castro Valley — Castro Valley
- Bay Area Breast Surgeons Inc — Emeryville
- Kaiser Permanente Hospital — Fontana
- Valley Medical Oncology Consultants-Fremont — Fremont
- Kaiser Permanente - Harbor City — Harbor City
- Kaiser Permanente-Irvine — Irvine
- Kaiser Permanente Los Angeles Medical Center — Los Angeles
- Kaiser Permanente-Cadillac — Los Angeles
- Contra Costa Regional Medical Center — Martinez
- El Camino Hospital — Mountain View
- Highland General Hospital — Oakland
- Alta Bates Summit Medical Center - Summit Campus — Oakland
- Bay Area Tumor Institute — Oakland
- Hematology and Oncology Associates-Oakland — Oakland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2008-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698815
The ClinicalTrials.gov registry entry for NCT00698815 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 2,390 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Recurrent Non-Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 3 interventions — of which Laboratory Biomarker Analysis is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00698815 reports 20 study locations spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00698815 about?
NCT00698815 is a clinical study titled "Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer". This randomized phase II trial studies pemetrexed disodium and sunitinib malate to compare how well they work when given alone or together as second-line therapy in treating patients with stage IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as pemetrexed disodium, work...
What is the current status of trial NCT00698815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2008-04-15.
What conditions does trial NCT00698815 study?
This clinical trial studies the following conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00698815?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pemetrexed Disodium (DRUG), Sunitinib Malate (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00698815?
This trial is sponsored by National Cancer Institute (NCI), which has 2,390 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00698815 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.